{
    "xml": "<topic id=\"PHP727\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/colestyramine\" basename=\"colestyramine\" title=\"COLESTYRAMINE\">\n<title>COLESTYRAMINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_592\" namespace=\"/interactions/list-of-drug-interactions/lipid-regulating-drugs/bile-acid-sequestrants/colestyramine\">Colestyramine</xref>\n</p>\n<data name=\"vtmid\">72824008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_591996686\" title=\"Bile acid sequestrants\">Bile acid sequestrants</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34564\" title=\"BILE ACID SEQUESTRANTS\" namespace=\"/drug-classes/bile-acid-sequestrants\">BILE ACID SEQUESTRANTS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n<p outputclass=\"synonyms\">Cholestyramine</p>\r\n</body>\n<topic id=\"PHP63602\" outputclass=\"indicationsAndDose\" rev=\"1.57\" parent=\"/drugs/colestyramine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Hyperlipidaemias, particularly type IIa, in patients who have not responded adequately to diet and other appropriate measures</p>\n<p outputclass=\"therapeuticIndication\">Primary prevention of coronary heart disease in men aged 35&#8211;59 years with primary hypercholesterolaemia who have not responded to diet and other appropriate measures</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 4&#8239;g daily, increased in steps of 4&#8239;g every 1&#8239;week; 12&#8211;24&#8239;g daily in 1&#8211;4 divided doses, adjusted according to response; maximum 36&#8239;g per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Pruritus associated with partial biliary obstruction and primary biliary cirrhosis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>4&#8211;8&#8239;g once daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Diarrhoea associated with Crohn&#8217;s disease, ileal resection, vagotomy, diabetic vagal neuropathy, and radiation</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 4&#8239;g daily, increased in steps of 4&#8239;g every 1&#8239;week; 12&#8211;24&#8239;g daily in 1&#8211;4 divided doses, adjusted according to response, if no response within 3 days an alternative therapy should be initiated; maximum 36&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Accelerated elimination of teriflunomide</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>8&#8239;g 3 times a day for 11 days; reduced to 4&#8239;g 3 times a day, dose should only be reduced if not tolerated.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Accelerated elimination of leflunomide (washout procedure)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>8&#8239;g 3 times a day for 11 days.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63681\" outputclass=\"contraindications\" rev=\"1.6\" parent=\"/drugs/colestyramine\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Complete biliary obstruction (not likely to be effective)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63594\" outputclass=\"interactions\" rev=\"1.10\" parent=\"/drugs/colestyramine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (colestyramine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63529\" outputclass=\"sideEffects\" rev=\"1.8\" parent=\"/drugs/colestyramine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Intestinal obstruction</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hyperchloraemic acidosis (on prolonged use)</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63714\" outputclass=\"directionsForAdministration\" rev=\"1.16\" parent=\"/drugs/colestyramine\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>The contents of each sachet should be mixed with at least 150&#8239;mL of water or other suitable liquid such as fruit juice, skimmed milk, thin soups, and pulpy fruits with a high moisture content.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Other drugs should be taken at least 1 hour before or 4&#8211;6 hours after colestyramine to reduce possible interference with absorption.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63574\" outputclass=\"patientAndCarerAdvice\" rev=\"1.16\" parent=\"/drugs/colestyramine\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patient counselling on administration is advised for colestyramine powder (avoid other drugs at same time).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP727-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/colestyramine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension, cream</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76957\" title=\"Powder\" namespace=\"/drugs/colestyramine/powder\">Powder</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP34469\" namespace=\"/drugs/teriflunomide\" title=\"TERIFLUNOMIDE\" count=\"1\" rel=\"backlink\">TERIFLUNOMIDE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP6596\" namespace=\"/drugs/leflunomide\" title=\"LEFLUNOMIDE\" count=\"1\" rel=\"backlink\">LEFLUNOMIDE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107735\" namespace=\"/guidance/prescribing-in-palliative-care\" title=\"Prescribing in palliative care\" count=\"1\" rel=\"backlink\">Prescribing in palliative care</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78209\" namespace=\"/treatment-summaries/biliary-disorders\" title=\"Biliary disorders\" count=\"1\" rel=\"backlink\">Biliary disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78231\" namespace=\"/treatment-summaries/acute-diarrhoea\" title=\"Acute diarrhoea\" count=\"1\" rel=\"backlink\">Acute diarrhoea</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78316\" namespace=\"/treatment-summaries/inflammatory-bowel-disease\" title=\"Inflammatory bowel disease\" count=\"1\" rel=\"backlink\">Inflammatory bowel disease</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78339\" namespace=\"/treatment-summaries/topical-local-antipruritics\" title=\"Topical local antipruritics\" count=\"1\" rel=\"backlink\">Topical local antipruritics</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_592\" namespace=\"/interactions/list-of-drug-interactions/lipid-regulating-drugs/bile-acid-sequestrants/colestyramine\" title=\"Colestyramine\" count=\"1\" rel=\"link\">Colestyramine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34564\" namespace=\"/drug-classes/bile-acid-sequestrants\" title=\"BILE ACID SEQUESTRANTS\" count=\"1\" rel=\"link\">BILE ACID SEQUESTRANTS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76957\" namespace=\"/drugs/colestyramine/powder\" title=\"Powder\" count=\"1\" rel=\"link\">Powder</xref>\n</links>\n</topic>",
    "id": "PHP727",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/colestyramine",
    "basename": "colestyramine",
    "title": "COLESTYRAMINE",
    "interactants": [
        {
            "id": "bnf_int_592",
            "label": "Colestyramine"
        }
    ],
    "vtmid": "72824008",
    "drugClassification": [
        "Bile acid sequestrants"
    ],
    "inheritsFromClass": [
        "BILE ACID SEQUESTRANTS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Cholestyramine"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Hyperlipidaemias, particularly type IIa, in patients who have not responded adequately to diet and other appropriate measures",
                        "html": "Hyperlipidaemias, particularly type IIa, in patients who have not responded adequately to diet and other appropriate measures"
                    },
                    {
                        "textContent": "Primary prevention of coronary heart disease in men aged 35&#8211;59 years with primary hypercholesterolaemia who have not responded to diet and other appropriate measures",
                        "html": "Primary prevention of coronary heart disease in men aged 35&#8211;59 years with primary hypercholesterolaemia who have not responded to diet and other appropriate measures"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 4 g daily, increased in steps of 4 g every 1 week; 12&#8211;24 g daily in 1&#8211;4 divided doses, adjusted according to response; maximum 36 g per day.",
                        "html": "<p>Initially 4&#8239;g daily, increased in steps of 4&#8239;g every 1&#8239;week; 12&#8211;24&#8239;g daily in 1&#8211;4 divided doses, adjusted according to response; maximum 36&#8239;g per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Pruritus associated with partial biliary obstruction and primary biliary cirrhosis",
                        "html": "Pruritus associated with partial biliary obstruction and primary biliary cirrhosis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "4&#8211;8 g once daily.",
                        "html": "<p>4&#8211;8&#8239;g once daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Diarrhoea associated with Crohn&#8217;s disease, ileal resection, vagotomy, diabetic vagal neuropathy, and radiation",
                        "html": "Diarrhoea associated with Crohn&#8217;s disease, ileal resection, vagotomy, diabetic vagal neuropathy, and radiation"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 4 g daily, increased in steps of 4 g every 1 week; 12&#8211;24 g daily in 1&#8211;4 divided doses, adjusted according to response, if no response within 3 days an alternative therapy should be initiated; maximum 36 mg per day.",
                        "html": "<p>Initially 4&#8239;g daily, increased in steps of 4&#8239;g every 1&#8239;week; 12&#8211;24&#8239;g daily in 1&#8211;4 divided doses, adjusted according to response, if no response within 3 days an alternative therapy should be initiated; maximum 36&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Accelerated elimination of teriflunomide",
                        "html": "Accelerated elimination of teriflunomide"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "8 g 3 times a day for 11 days; reduced to 4 g 3 times a day, dose should only be reduced if not tolerated.",
                        "html": "<p>8&#8239;g 3 times a day for 11 days; reduced to 4&#8239;g 3 times a day, dose should only be reduced if not tolerated.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Accelerated elimination of leflunomide (washout procedure)",
                        "html": "Accelerated elimination of leflunomide (washout procedure)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "8 g 3 times a day for 11 days.",
                        "html": "<p>8&#8239;g 3 times a day for 11 days.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Complete biliary obstruction (not likely to be effective)",
                "html": "Complete biliary obstruction (not likely to be effective)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (colestyramine).",
                "html": "<p>Appendix 1 (colestyramine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Intestinal obstruction",
                        "html": "Intestinal obstruction",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Hyperchloraemic acidosis (on prolonged use)",
                        "html": "Hyperchloraemic acidosis (on prolonged use)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "The contents of each sachet should be mixed with at least 150 mL of water or other suitable liquid such as fruit juice, skimmed milk, thin soups, and pulpy fruits with a high moisture content.",
                "html": "<p>The contents of each sachet should be mixed with at least 150&#8239;mL of water or other suitable liquid such as fruit juice, skimmed milk, thin soups, and pulpy fruits with a high moisture content.</p>"
            },
            {
                "type": "directionsForAdministration",
                "textContent": "Other drugs should be taken at least 1 hour before or 4&#8211;6 hours after colestyramine to reduce possible interference with absorption.",
                "html": "<p>Other drugs should be taken at least 1 hour before or 4&#8211;6 hours after colestyramine to reduce possible interference with absorption.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patient counselling on administration is advised for colestyramine powder (avoid other drugs at same time).",
                "html": "<p>Patient counselling on administration is advised for colestyramine powder (avoid other drugs at same time).</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension",
                "cream"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76957",
                "label": "Powder",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP34469",
                "label": "TERIFLUNOMIDE",
                "type": "drug"
            },
            {
                "id": "PHP6596",
                "label": "LEFLUNOMIDE",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP107735",
                "label": "Prescribing in palliative care",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78209",
                "label": "Biliary disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78231",
                "label": "Acute diarrhoea",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78316",
                "label": "Inflammatory bowel disease",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78339",
                "label": "Topical local antipruritics",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_592",
                "label": "Colestyramine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34564",
                "label": "BILE ACID SEQUESTRANTS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76957",
                "label": "Powder",
                "type": "medicinalForm"
            }
        ]
    }
}